Neurona Therapeutics announces plans to initiate Phase 3 EPIC trial for NRTX-1001, the first investigational human cell therapy for drug-resistant epilepsy, following FDA's RMAT designation.
Wayne State University enrolled the first Michigan patient in a Phase I/II trial testing stem cell-derived interneuron implantation to reduce seizure frequency.